Heartbeam (BEAT) Registration Filing summary

Company overview and business model

• Focuses on ambulatory cardiac monitoring with a proprietary 3D ECG platform enabling synthesized 12-lead ECGs outside healthcare facilities.

• Initial product is an FDA-cleared, cable-free, credit card-sized ECG device with cloud-based algorithms and a physician portal.

• Targets high-risk coronary artery disease monitoring, arrhythmia assessment, and future heart attack detection.

• Growth strategy includes limited launch in 2026, expansion into heart attack detection, extended wear patch, and AI-based diagnostics.

• Employs 17 staff as of January 2026, with commercialization led by an experienced Chief Commercial Officer.

Financial performance and metrics

• As of March 11, 2026, 41,087,871 shares of common stock are outstanding, held by approximately 45 shareholders.

• Common stock last traded at $1.47 per share on March 12, 2026, on Nasdaq Capital Market.

• Financial statements for 2024 and 2025 audited by independent firms, both including going concern explanatory paragraphs.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.